IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
A phase 1/2 trial of Rituximab, Daratumumab, Aldesleukin in multiple myeloma and hodgkin lymphoma, run by Indapta Therapeutics, INC., now recruiting.
Overview
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers is a phase 1/2 interventional study registered as NCT06119685 by Indapta Therapeutics, INC., with 128 participants planned, started 2023-10-25 and due to reach its primary completion in 2025-12-30. Interventions recorded: IDP-023, Rituximab, Daratumumab, Interleukin-2, Cyclophosphamide. Conditions listed: NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Shares Fludarabine, Cyclophosphamide, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Shares Fludarabine, Cyclophosphamide, Non-Hodgkin lymphoma (all types).
- TrialA Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
Shares Aldesleukin (high-dose IL-2), Daratumumab, Multiple myeloma.
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Monotherapy or Combined With Standard of Care Th
Shares Rituximab, Cyclophosphamide, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neopl
Shares Rituximab, Cyclophosphamide, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Shares Fludarabine, Cyclophosphamide, Multiple myeloma.
- TrialA Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
Shares Rituximab, Cyclophosphamide, Non-Hodgkin lymphoma (all types), Hodgkin lymphoma.
- TrialA Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Shares Fludarabine, Rituximab, Cyclophosphamide.